Research programme: thrombin inhibitors - Thromgen
Alternative Names: Arg-Pro-Pro-Gly-Phe; MAP4-RPPGF; RPPGF; Thrombostatin™Latest Information Update: 30 Apr 2007
At a glance
- Originator Temple University; University of Michigan
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute coronary syndromes; Thrombosis
Most Recent Events
- 26 Jul 2005 Preclinical trials in Acute coronary syndromes in USA (IV)
- 26 Jul 2005 Preclinical trials in Thrombosis in USA (PO)